COMPASS Pathways

Compass Pathways' stock rose to a 52-week high of $15.40 and was last quoted at $15.42 with a market capitalization of about $2.11 billion, after gaining 172% over the past year. InvestingPro rates the stock as overvalued and points to high volatility (beta 2.55). Compass reported positive long-term results from Part C of the phase-3 study of COMP360, with an average 13-point reduction on the MADRS after 52 weeks, and disclosed cash holdings of $433 million, which are expected to fund operations through 2028. Jefferies reiterated a buy rating with a $18.00 target and sees a 75–85% probability of FDA approval; Oppenheimer maintained an outperform rating with a $20.00 target. » Más en de.investing.com

Compass Pathways, in collaboration with the U.S. Department of Veterans Affairs, is launching the multicenter, double-blind, randomized PIVOT study to evaluate COMP360 psilocybin in veterans with treatment-resistant depression, including those with comorbid PTSD. Two doses of COMP360 will be compared, with an option for a second unblinded dose after four weeks; the primary endpoint is depression severity measured by MADRS. Compass will supply the drug as well as training and counseling materials; the study will run at five VA sites under the lead of the Birmingham VA Health Care System. » Más en de.investing.com

A post-hoc analysis of an open-label phase 2 study of COMP360 in PTSD found that 78% of treatment sessions took place in silence and verbal interactions between participants and therapists were minimal. Support was predominantly non-directive and focused on presence, soothing and affirmation to promote autonomy in the introspective state. Compass Pathways has established a training and mentoring program for therapists; COMP360 holds Breakthrough Therapy designation in the US and an innovative approval in the UK for treatment‑resistant depression. » Más en de.investing.com